A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Alpelisib BYL719 in Combination with Nab-Paclitaxel in Patients with Advanced Triple Negative Breast Cancer with Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha PIK3CA Mutation or Phosphatase and Tensin Homolog Protein PTEN Loss Without PIK3CA Mutation
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer SCARLET, A Randomized Phase III Study
Phase III Trial of Neoadjuvant Durvalumab NSC 778709 plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh MP2 Hormone Receptor HR Positive / Human Epidermal Growth Factor Receptor HER2 Negative Stage II-III Breast Cancer
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Phase III Open-label, Randomized Study of Datopotamab Deruxtecan Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy TROPION-Breast03